People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found. The study also highlighted a need for ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of cases, patients with CLL will develop lymphoma, a complication known as ...

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The non-covalent ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Results from the BRUIN CLL-314 study comparing Jaypirca (pirtobrutinib) to Imbruvica (ibrutinib) – the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve ...